{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T10:00:47Z","timestamp":1760954447413,"version":"build-2065373602"},"reference-count":31,"publisher":"BMJ","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Epidemiol Community Health"],"published-print":{"date-parts":[[2001,4,1]]},"abstract":"<jats:sec>\n                  <jats:title>STUDY OBJECTIVES<\/jats:title>\n                  <jats:p>The objective of this study was to evaluate the effectiveness of a mass vaccination programme carried out in Catalonia (Spain) in the last quarter of 1997 in response to an upsurge of serogroup C meningococcal disease (SCMD).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>DESIGN<\/jats:title>\n                  <jats:p>Vaccination coverage in the 18 month to 19 years age group was investigated by means of a specific vaccination register. Vaccination effectiveness was calculated using the prospective cohort method. Cases of SCMD were identified on the basis of compulsory reporting and microbiological notification by hospital laboratories. Vaccination histories were investigated in all cases. Unadjusted and age adjusted vaccination effectiveness referred to the time of vaccination and the corresponding 95% confidence intervals (CI) were estimated at 6, 12, 18 and 24 months of follow up.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>SETTING<\/jats:title>\n                  <jats:p>All population aged 18 months to 19 years of Catalonia.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>MAIN RESULTS<\/jats:title>\n                  <jats:p>A total of seven cases of SCMD were detected at six months of follow up (one in the vaccinated cohort), 12 cases at 12 months (one in the vaccinated cohort), 19 cases at 18 months (two in the vaccinated cohort) and 24 at 24 months (two in the vaccinated cohort). The age adjusted effectiveness was 84% (95%CI 30, 97) at six months, 92% (95%CI 63, 98) at 12 months, 92% (95% CI 71, 98) at 18 months and 94% (95%CI 78, 98) at 24 months. In the target population, cases have been reduced by more than two thirds (68%) two years after the vaccination programme. In the total population the reduction was 43%.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>CONCLUSION<\/jats:title>\n                  <jats:p>Vaccination effectiveness has been high in Catalonia, with a dramatic reduction in disease incidence in the vaccinated cohort accompanied by a relevant reduction in the overall population. Given that vaccination coverage was only 54.6%, it may be supposed that this vaccination effectiveness is attributable, in part, to the herd immunity conferred by the vaccine.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/jech.55.4.283","type":"journal-article","created":{"date-parts":[[2002,7,27]],"date-time":"2002-07-27T06:33:18Z","timestamp":1027751598000},"page":"283-287","source":"Crossref","is-referenced-by-count":22,"title":["Dramatic decline of serogroup C meningococcal disease incidence in Catalonia (Spain) 24 months after a mass vaccination programme of children and young people"],"prefix":"10.1136","volume":"55","author":[{"given":"L","family":"Salleras","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Dom\u00ednguez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G","family":"Prats","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I","family":"Parron","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P","family":"Mu\u00f1oz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2001,4,1]]},"reference":[{"key":"2025100704481489000_55.4.283.1","unstructured":"Dom\u00ednguez A Fern\u00e1ndez-Crehuet J Prats G (1998) Meningococcal vaccine. in Preventive vaccinations. ed Salleras L (Masson, Barcelona), pp 337\u2013368."},{"key":"2025100704481489000_55.4.283.2","doi-asserted-by":"crossref","first-page":"71","DOI":"10.2807\/esm.02.10.00146-en","article-title":"Changing epidemiology of meningococcal disease in Spain, 1989\u20131997.","volume":"2","author":"Mateo","year":"1997","journal-title":"Eurosurveillance"},{"key":"2025100704481489000_55.4.283.3","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/S0213-9111(97)71303-7","article-title":"Analysis of the management of meningoccus C vaccination campaign in Galicia, 1996\u20131997.","volume":"11","author":"Farjas","year":"1997","journal-title":"Gac Sanit"},{"key":"2025100704481489000_55.4.283.4","doi-asserted-by":"crossref","first-page":"S56","DOI":"10.1016\/S0264-410X(99)00294-7","article-title":"Control of serogroup C meningococcal disease by mass vaccination in Catalonia (Spain).","volume":"17","author":"Salleras","year":"1999","journal-title":"Vaccine"},{"key":"2025100704481489000_55.4.283.5","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1093\/oxfordjournals.epirev.a036023","article-title":"Assessing vaccine efficacy in the field.","volume":"10","author":"Orenstein","year":"1988","journal-title":"Epidemiol Rev"},{"key":"2025100704481489000_55.4.283.6","unstructured":"Institut d'Estad\u00edstica de Catalunya (1998) Annual Statistics of Catalonia 1998. (Generalitat de Catalunya, Barcelona)."},{"key":"2025100704481489000_55.4.283.7","unstructured":"Kleinbaum DG Kupper LL Morgenstern H (1982) Epidemiologic research. Principles and quantitative methods. (Van Nostrand Reinhold, New York), pp 297\u2013299."},{"key":"2025100704481489000_55.4.283.8","unstructured":"Clayton D Hills M (1993) Statistical models in epidemiology. (Oxford University Press, Oxford), pp 141\u2013164."},{"key":"2025100704481489000_55.4.283.9","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1056\/NEJM197002192820803","article-title":"Prevention of meningococcal disease by group C polysaccharide vaccine.","volume":"282","author":"Artenstein","year":"1970","journal-title":"N Engl J Med"},{"key":"2025100704481489000_55.4.283.10","first-page":"279","article-title":"Meningococcal infections. 2. Field trial of group C meningococcal polysaccharide vaccine in 1969\u201370.","volume":"45","author":"Gold","year":"1971","journal-title":"Bull World Health Organ"},{"key":"2025100704481489000_55.4.283.11","doi-asserted-by":"publisher","DOI":"10.1016\/0264-410X(93)90236-Q"},{"key":"2025100704481489000_55.4.283.12","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/0264-410X(93)90236-Q","article-title":"Dramatic reduction of meningococcal meningitis among military recruits in Italy after introduction of specific vaccination.","volume":"11","author":"Biselli","year":"1993","journal-title":"Vaccine"},{"key":"2025100704481489000_55.4.283.13","doi-asserted-by":"publisher","DOI":"10.1001\/jama.279.6.435"},{"key":"2025100704481489000_55.4.283.14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197709292971302"},{"key":"2025100704481489000_55.4.283.15","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1056\/NEJM197709292971302","article-title":"Clinical efficacy of meningococcus group A capsular polysaccharide vaccine in children three months to five years of age.","volume":"297","author":"Peltola","year":"1977","journal-title":"N Engl J Med"},{"key":"2025100704481489000_55.4.283.16","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/S0140-6736(75)92125-X","article-title":"Effect of group A meningococcal vaccines in army recruits in Finland.","volume":"ii","author":"M\u00e4kela","year":"1975","journal-title":"Lancet"},{"key":"2025100704481489000_55.4.283.17","first-page":"365","article-title":"Seroprevalence of bactericidal antibodies against meningococcus C in Cantabria 10 months after a mass vaccination campaign.","volume":"72","author":"Gonz\u00e1lez de Aledo","year":"1998","journal-title":"Rev Esp Salud P\u00fablica"},{"key":"2025100704481489000_55.4.283.18","first-page":"59","article-title":"Study of seroconversion efficacy and length of vaccine immunity against serogroup C meningococcus.","volume":"72 (suppl)","author":"Ram\u00edrez","year":"1998","journal-title":"Rev Esp Salud P\u00fablica"},{"key":"2025100704481489000_55.4.283.19","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(96)70389-X"},{"key":"2025100704481489000_55.4.283.20","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/173.4.1009"},{"key":"2025100704481489000_55.4.283.21","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1093\/infdis\/173.4.1009","article-title":"Analysis of meningococcal serogroup C-specific antibody levels in British Columbian children and adolescents.","volume":"173","author":"Mitchell","year":"1996","journal-title":"J Infect Dis"},{"key":"2025100704481489000_55.4.283.22","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1128\/IAI.66.6.2453-2459.1998","article-title":"Age-dependent Neisseria meningitidis serogroup C. Class-specific antibody concentration and bactericidal titers in sera from young children from Montana immunised with a licensed polysaccharide vaccine.","volume":"66","author":"Maslanka","year":"1998","journal-title":"Infect Immun"},{"key":"2025100704481489000_55.4.283.23","unstructured":"Zollinger WD (1997) New and improved vaccines against meningococcal disease. in New generation vaccines. eds Levine MM Woodrow GC Kaper JB (Marcel Dekker, New York), 2nd ed. pp 469\u2013488."},{"key":"2025100704481489000_55.4.283.24","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/171.3.632"},{"key":"2025100704481489000_55.4.283.25","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/174.6.1360"},{"key":"2025100704481489000_55.4.283.26","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1996.03530430043037"},{"key":"2025100704481489000_55.4.283.27","doi-asserted-by":"publisher","DOI":"10.1016\/S1201-9712(97)90079-5"},{"key":"2025100704481489000_55.4.283.28","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/175.1.200"},{"key":"2025100704481489000_55.4.283.29","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1093\/infdis\/175.1.200","article-title":"Induction of immunologic memory in Gambian children by vaccination in infancy with a group A plus group C meningococcal polysaccharide-protein conjugate vaccine.","volume":"175","author":"Leach","year":"1997","journal-title":"J Infect Dis"},{"key":"2025100704481489000_55.4.283.30","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0258(19961115)15:21<2379::AID-SIM457>3.0.CO;2-L"},{"key":"2025100704481489000_55.4.283.31","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1002\/(SICI)1097-0258(19961115)15:21<2379::AID-SIM457>3.0.CO;2-L","article-title":"Comparing methods for calculating confidence intervals for vaccine efficacy.","volume":"15","author":"Ewell","year":"1996","journal-title":"Stat Med"}],"container-title":["Journal of Epidemiology and Community Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jech.55.4.283","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T11:48:29Z","timestamp":1759837709000},"score":1,"resource":{"primary":{"URL":"https:\/\/jech.bmj.com\/lookup\/doi\/10.1136\/jech.55.4.283"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,4,1]]},"references-count":31,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2001,4,1]]},"published-print":{"date-parts":[[2001,4,1]]}},"alternative-id":["10.1136\/jech.55.4.283"],"URL":"https:\/\/doi.org\/10.1136\/jech.55.4.283","relation":{},"ISSN":["0143-005X","1470-2738"],"issn-type":[{"type":"print","value":"0143-005X"},{"type":"electronic","value":"1470-2738"}],"subject":[],"published":{"date-parts":[[2001,4,1]]}}}